The healthcare industry, especially its biotechnology corner, has been a great performer so far this year as evident from an impressive 43.64% gain in S&P biotechnology select industry index in the last one year (as of November 25, 2013). The credit for this bull run can at least partially be traced back to the approval of the Affordable Care Act in 2010.
The legislation, often known as ‘Obamacare’, was aimed at bolstering the number of insured Americans, should boost demand for Pharma and Medicare industry as a whole. The enrollment to purchase insurance plan under the law was carried out in October.
Also, increasing merger & acquisition activities, new investment havens in the under-penetrated emerging markets, several new drug approvals and steadily rising global health care spending assisted the sector to outperform the broader market.
In fact, to account for the rise in aging population and the consequent higher rates of chronic disease, the sector will likely witness even more demand ahead. This corner of the healthcare space has posted solid earnings on good fundamentals, resulting in soaring stock prices.
Robust earnings from some of the companies in the sector such as, Alexion Pharmaceuticals Inc (ALXN), Amgen Inc (AMGN) and Merck & Co. (MRK) as well as a bullish outlook on drug approval from the likes of Gilead Sciences, Inc. (GILD) pushed the sector into a rally (read: 4 Ways to Play the Bullish Trend in Healthcare with ETFs).
Further, with ‘taper hold’ in the U.S. and cheap dollars available around, investors are aggressively picking high-flying sectors like healthcare, technology and consumer discretionary in order to reap as much capital appreciation as they can. This was another reason behind the exciting run of biotech equities.
Affordable Care Act or Obamacare was debated during the recent ‘government shutdown’ leading to a slight pullback in most of the biotech funds in early October. Now with the economy partially averting the shutdown, the sector seems to be back on track once more.
If these were not enough, within the Zacks Industry classification, the rank of the concerned MED-BIOMED/GENE industry is currently #81. The rank is in the top 1/3 of all 260 plus industries ranked, highlighting the group’s near-term Positive outlook (read: About Zacks Industry Rank).
How to Play?
Investors looking to gain exposure to this uptrend may want to take a look at the following ETFs, as these offer concentrated exposure to biotechnology companies. The biotech ETFs mentioned below could be worthwhile as all these have a Zacks ETF Rank #1 (Strong Buy). The gains out of these funds were double the return offered by the broader market fund SPDR S&P 500 (SPY) in the same time frame.
iShares Nasdaq Biotechnology ETF (IBB)
This fund provides exposure to 119 companies by tracking the Nasdaq Biotechnology Index. With AUM of more than $4.00 billion and average daily volume of about 700,000 shares a day, this is by far one of the largest and the most popular ETFs in the biotech space. The ETF charges a reasonable 48 bps in annual fees.
The product has concentration in the top 10 holdings which account for as much as about 60% of the total. Top three holdings Biogen (BIIB), GILD and CELG make up for about one-fourth share of the fund. Growth stocks are once again a big part of the portfolio with 78% of the assets while large cap calls for 60% exposure (see more in the Zacks ETF Center).
In terms of performance, IBB returned as much as 62% in the year-to-date time frame. The fund carries a Zacks ETF Rank #1 (Strong Buy) with a medium risk outlook.
Market Vectors Biotech ETF (BBH)
This fund looks to track the Market Vectors US Listed Biotech 25 Index, holding 26 securities in the basket. With an AUM of $473.3 million and an average trading volume of nearly 120,000 shares a day, the fund offers moderate liquidity.
The fund is a cheaper option as it charges a 35 bps fee per year, much lower than the average expense ratio of about 45 basis points a year. The product is largely concentrated in its top 10 securities with around 70% of exposure and is tilted toward large cap and growth stocks.
GILD takes the top spot with 14.6% coverage, closely followed by AMGN and Celgene (CELG) at 11.72% and 8.91%, respectively. The ETF added a massive 63% in the year-to-date time frame (as of November 25, 2013). The fund carries a Zacks ETF Rank #1 (Strong Buy) with a high risk outlook.
PowerShares Dynamic Biotechnology & Genome Portfolio (PBE)
This ETF follows the Dynamic Biotechnology & Genome Intellidex Index. The product has a somewhat low volume of 80,000 shares a day, but a decent level of about $276 million in assets under management. The fund charges 63 bps in fees and expenses from investors. It is a slightly pricey option.
The fund is tilted toward growth stocks. The product has added an impressive 64.2% in the year-to-date frame. The fund has a Zacks ETF Rank #1 (Strong Buy) with a medium risk outlook (read: Top Biotechnology ETF in Focus: PBE).
In a nutshell, the sector is poised to surge in the near term. Investors should note that, the debt ceiling debate will likely resume early next year again raising some concerns over Obamacare – one of the drivers of the sector. However, this should not be much of an issue as long as generic drivers of biotech companies remain intact and investor demand for growth securities remains robust.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Read the analyst report on IBB
Read the analyst report on BBH
Read the analyst report on PBE
Read the analyst report on GILD
Read the analyst report on AMGN
Zacks Investment Research
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
- Personal Investing Ideas & Strategies